Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany (PRNewswire) - Dec 4, 2025 - "The Munich Regional Court's 7th Civil Division found that there is imminent infringement for Keytruda SC in Germany regarding one of Halozyme's MDASE patents in Europe, European Patent No. 2 797 622 (EP 622). As a consequence, Merck's launch activities for Keytruda SC in Germany that are within the scope of the order must be halted...Importantly, patients who want to use Keytruda will have access to the IV version of Keytruda, which is not covered by Halozyme's patent or the court's injunction order....The MDASE patents are not included in Halozyme's ENHANZE licensing program and are distinct from its ENHANZE patents. Therefore, the outcome of the infringement lawsuit against Merck will not impact ENHANZE..."
Patent • Biliary Tract Cancer • Cervical Cancer • Cholangiocarcinoma • Colorectal Cancer • Endometrial Cancer • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Hodgkin Lymphoma • Melanoma • Microsatellite Instability • Non Small Cell Lung Cancer • Renal Cell Carcinoma • Triple Negative Breast Cancer • Urothelial Cancer
|